Study archive
Published Sermorelin dosage records
These amounts describe experiments in particular populations. Personal treatment requires a clinician's assessment; this archive supplies no regimen.
Childhood growth study
The multicenter trial in prepubertal children with growth-hormone deficiency used 30 micrograms/kg/day of subcutaneous GHRH(1-29), administered at bedtime. The question was whether treatment accelerated linear growth during the first year, and height velocity increased.
The study population anchors the amount for me. This was pediatric deficiency research with growth as its endpoint. Transplanting its figure into an adult wellness plan would discard the very context that makes the paper interpretable.
Older-men hormone experiment
In Corpas and colleagues' study, healthy older men received 0.5 milligrams and 1 milligram of subcutaneous GHRH(1-29) twice daily for 14 days. The investigators measured GH and IGF-1 across 24 hours, with young men providing comparison values. The higher studied amount brought hormone parameters toward the younger group; fasting glucose was unchanged.
That brief endocrine experiment documents a hormone response. It supplies no validated adult anti-aging regimen or long-term safety conclusion.
Intravenous pharmacokinetics
The Wilton study in 30 healthy men tested intravenous GHRH(1-29)-NH2 at 0.25-2 micrograms/kg. Significant GH release appeared at 0.25 micrograms/kg, and maximal release at 1-2 micrograms/kg. The plasma half-life was about 10-12 minutes, with GH elevated for about 3 hours.
Intranasal bioavailability was only 3-5% in that work. In a separate study of a norleucine-modified GHRH analog, subcutaneous and intranasal doses needed to be tenfold and thirtyfold higher, respectively, than intravenous doses for the studied response. These were experimental comparisons involving a related analog, not a conversion formula for personal use.
Timing and preparation
The bedtime choice in the childhood trial reflected interest in the natural nocturnal GH pulse. Continuous delivery produced a different result: the infusion study in children found an initial increase followed by declining GH secretion. My suspicion of any universal schedule comes from differences like these.
Study supplies used freeze-dried sermorelin acetate because peptide solutions can degrade in water. The pharmacokinetic literature describes preparation context, while compounded sterile preparations are subject to USP 797 standards. This entry records those features without providing mixing, injection or storage instructions for an individual preparation.